These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 9546419

  • 1. Assessment of the effect of the oral iron chelator deferiprone on asymptomatic Plasmodium falciparum parasitemia in humans.
    Thuma PE, Olivieri NF, Mabeza GF, Biemba G, Parry D, Zulu S, Fassos FF, McClelland RA, Koren G, Brittenham GM, Gordeuk VR.
    Am J Trop Med Hyg; 1998 Mar; 58(3):358-64. PubMed ID: 9546419
    [Abstract] [Full Text] [Related]

  • 2. Deferiprone (L1) as an adjuvant therapy for Plasmodium falciparum malaria.
    Mohanty D, Ghosh K, Pathare AV, Karnad D.
    Indian J Med Res; 2002 Jan; 115():17-21. PubMed ID: 12424933
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic disposition of the oral iron chelator deferiprone in the domestic pigeon (Columba livia).
    Whiteside DP, Barker IK, Conlon PD, Tesoro A, Thiessen JJ, Mehren KG, Jacobs RM, Spino M.
    J Avian Med Surg; 2007 Jun; 21(2):121-9. PubMed ID: 18065133
    [Abstract] [Full Text] [Related]

  • 4. Orally active iron chelators.
    Merson L, Olivier N.
    Blood Rev; 2002 Jun; 16(2):127-34. PubMed ID: 12127956
    [Abstract] [Full Text] [Related]

  • 5. A risk-benefit assessment of iron-chelation therapy.
    Porter JB.
    Drug Saf; 1997 Dec; 17(6):407-21. PubMed ID: 9429839
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic disposition of the oral iron chelator deferiprone in the white leghorn chicken.
    Whiteside DP, Barker IK, Conlon PD, Tesoro A, Thiessen JJ, Mehren KG, Jacobs RM, Spino M.
    J Avian Med Surg; 2007 Jun; 21(2):110-20. PubMed ID: 18065132
    [Abstract] [Full Text] [Related]

  • 7. Antimalarial iron chelator, FBS0701, shows asexual and gametocyte Plasmodium falciparum activity and single oral dose cure in a murine malaria model.
    Ferrer P, Tripathi AK, Clark MA, Hand CC, Rienhoff HY, Sullivan DJ.
    PLoS One; 2012 Jun; 7(5):e37171. PubMed ID: 22629364
    [Abstract] [Full Text] [Related]

  • 8. Clinical evaluation of the oral iron chelator deferiprone for the potential treatment of iron overload in bird species.
    Whiteside DP, Barker IK, Mehren KG, Jacobs RM, Conlon PD.
    J Zoo Wildl Med; 2004 Mar; 35(1):40-9. PubMed ID: 15193072
    [Abstract] [Full Text] [Related]

  • 9. Iron-chelation therapy with oral deferiprone in patients with thalassemia major.
    Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, McClelland RA, Liu PP, Templeton DM, Koren G.
    N Engl J Med; 1995 Apr 06; 332(14):918-22. PubMed ID: 7877649
    [Abstract] [Full Text] [Related]

  • 10. The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels.
    Fassos FF, Klein J, Fernandes D, Matsui D, Olivieri NF, Koren G.
    Int J Clin Pharmacol Ther; 1996 Jul 06; 34(7):288-92. PubMed ID: 8832304
    [Abstract] [Full Text] [Related]

  • 11. Iron chelation therapy.
    Hoffbrand AV, Wonke B.
    J Intern Med Suppl; 1997 Jul 06; 740():37-41. PubMed ID: 9350180
    [Abstract] [Full Text] [Related]

  • 12. Changes in transferrin saturation after treatment with the oral iron chelator deferiprone in patients with iron overload.
    al-Refaie FN, De Silva CE, Wonke B, Hoffbrand AV.
    J Clin Pathol; 1995 Feb 06; 48(2):110-4. PubMed ID: 7745107
    [Abstract] [Full Text] [Related]

  • 13. Liver iron depletion and toxicity of the iron chelator deferiprone (L1, CP20) in the guinea pig.
    Wong A, Alder V, Robertson D, Papadimitriou J, Maserei J, Berdoukas V, Kontoghiorghes G, Taylor E, Baker E.
    Biometals; 1997 Oct 06; 10(4):247-56. PubMed ID: 9353871
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of deferiprone in patients with β-thalassaemia: impact of splenectomy and iron status.
    Limenta LM, Jirasomprasert T, Jittangprasert P, Wilairat P, Yamanont P, Chantharaksri U, Fucharoen S, Morales NP.
    Clin Pharmacokinet; 2011 Jan 06; 50(1):41-50. PubMed ID: 21028920
    [Abstract] [Full Text] [Related]

  • 15. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
    Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T, Sheppard L.
    Br Med J (Clin Res Ed); 1987 Dec 12; 295(6612):1509-12. PubMed ID: 3122880
    [Abstract] [Full Text] [Related]

  • 16. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA, Foster RH.
    Drugs; 1999 Sep 12; 58(3):553-78. PubMed ID: 10493280
    [Abstract] [Full Text] [Related]

  • 17. An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major.
    Diav-Citrin O, Atanackovic G, Koren G.
    Ther Drug Monit; 1999 Feb 12; 21(1):74-81. PubMed ID: 10051057
    [Abstract] [Full Text] [Related]

  • 18. Oral deferiprone for iron chelation in people with thalassaemia.
    Roberts DJ, Brunskill SJ, Doree C, Williams S, Howard J, Hyde CJ.
    Cochrane Database Syst Rev; 2007 Jul 18; (3):CD004839. PubMed ID: 17636775
    [Abstract] [Full Text] [Related]

  • 19. The antimalarial effect of iron chelators: studies in animal models and in humans with mild falciparum malaria.
    Hershko C, Gordeuk VR, Thuma PE, Theanacho EN, Spira DT, Hider RC, Peto TE, Brittenham GM.
    J Inorg Biochem; 2007 Jul 18; 47(3-4):267-77. PubMed ID: 1431886
    [Abstract] [Full Text] [Related]

  • 20. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload.
    Kontoghiorghes GJ, Aldouri MA, Sheppard L, Hoffbrand AV.
    Lancet; 1987 Jun 06; 1(8545):1294-5. PubMed ID: 2884415
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.